Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Excess prepregnancy maternal BMI tied to interruption of breastfeeding

12 Apr 2018

Excess maternal body mass index (BMI) during prepregnancy seems to be associated with cessation of exclusive breastfeeding (EBF), according to a recent study.

Researchers performed a systematic review across six databases – PubMed, Scopus, Science Direct, LILACS, CINAHL and Web of Science – and identified 17 eligible studies, which were then subjected to a meta-analysis. Univariate meta-regression was used to determine the pooled effect of maternal prepregnancy BMI on EBF.

The pooled analysis showed that mothers with excess BMI prior to pregnancy were significantly more likely to interrupt EBF than mothers with normal BMI (effect size, 1.60; 95 percent CI, 1.47–1.74; p=0.000).

In general, the individual studies showed a similar trend, with the strongest effect size being 5.61 (4.31–7.66), reflecting the effect of overweight on EBF.

Moreover, the effect remained strong and significant even after excluding three studies with the strictest definition of EBF: mothers with excess BMI were approximately 60-percent more likely to interrupt EBF than their normal-weight counterparts.

“More studies are needed, mainly to assess the cessation of EBF and [for] greater comparability with respect to the cutoff point of EBF duration. There is also a need to use comparable cutoff points for the classification of prepregnancy maternal BMI,” said researchers.

“Further efforts to understand the possible determinants, confounders and even mediators of this association should also be emphasized,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
18 Jun 2019
The aromatase inhibitor anastrozole shows promise in the treatment of children with congenital adrenal hyperplasia, reducing bone age advancement without adversely affecting bone mineral density and visceral adipose tissue, as shown in a recent study.
20 hours ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, Yesterday
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.